Inactive Instrument

Depomed Inc Stock price Nasdaq

Equities

US2499081048

Pharmaceuticals

Sales 2024 * 117M Sales 2025 * 130M Capitalization 91.13M
Net income 2024 * -11M Net income 2025 * 1M EV / Sales 2024 * 0.78 x
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * 0.7 x
P/E ratio 2024 *
-7.99 x
P/E ratio 2025 *
192 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 98.37%
More Fundamentals * Assessed data
Dynamic Chart
Managers TitleAgeSince
Chief Executive Officer 63 19-01-31
Director of Finance/CFO 40 19-06-30
Chief Tech/Sci/R&D Officer - 23-03-05
Members of the board TitleAgeSince
Chairman 72 03-10-31
Director/Board Member 71 16-09-30
Director/Board Member 62 17-02-28
More insiders
Assertio Holdings, Inc. is a commercial pharmaceutical company offering differentiated products to patients. The Company has built its commercial portfolio through acquisition or licensing of approved products. Its comprehensive commercial capabilities include marketing through both a sales force and a non-personal promotion model, market access through payor contracting and trade and distribution. The Company’s primary marketed products include ROLVEDONTM (eflapegrastim-xnst) injection for subcutaneous use, INDOCIN (indomethacin) Suppositories, INDOCIN (indomethacin) Oral Suspension, Sympazan (clobazam) oral film, Otrexup (methotrexate) injection for subcutaneous use, SPRIX (ketorolac tromethamine) Nasal Spray, CAMBIA (diclofenac potassium for oral solution) and Zipsor (diclofenac potassium) Liquid filled capsules. INDOCIN (indomethacin) Suppositories and INDOCIN (indomethacin) Oral Suspension products are nonsteroidal anti-inflammatory drugs (NSAID).
Related indices
More about the company